Cancer-focused Parabilis’ upsized $670M IPO breaks new for record for biotechs Read more →

Sanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continue Read more →

Fueled by M&A and partnerships, biotech is poised for continued growth: EY Read more →